Nuvilex Release: Completed Pancreatic Cancer Phase 1-2 Trial Concluded the Encapsulated Cells Produced Chemotherapy That May Treat Downstream Micro Metastatic Disease
SILVER SPRING, Md.--(BUSINESS WIRE)--Nuvilex, Inc. (OTCQB:NVLX), an emerging biotechnology provider of cell and gene therapy solutions, discussed today the proprietary Cell-in-a-Box® technology, being acquired from SG Austria, that was used for the pancreatic cancer clinical trial and may have an effect on downstream micro metastatic disease.